New LaunchJun 1, 2026, 06:06 AM
EUDA Health Launches Regenixé Mask, Expands Helixé Product Line
AI Summary
EUDA Health Holdings Limited announced the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, expanding its Helixé product line. Developed by Chemokine Pte Ltd, for which EUDA holds exclusive global distributorship, the mask utilizes iPSC-derived skin stem cell secretome technology. EUDA aims to capitalize on the growing global face mask market, estimated at $7.95 billion in 2026 and projected to reach $9.08 billion by 2031, by leveraging its established distribution networks in Malaysia and China to drive sales across the Asia-Pacific region.
Key Highlights
- EUDA Health launched the Regenixé iPSC-derived Skin Stem Cell Secretome Mask.
- The new mask expands the Helixé product line, for which EUDA holds exclusive global distributorship.
- The global face mask market is estimated at $7.95 billion in 2026.
- The market is forecast to reach $9.08 billion by 2031.
- Asia-Pacific is a leading region for facial masks and skincare products.
- EUDA will leverage its distribution networks in Malaysia and China for sales.
Price Impact
More from EUDA